Olainfarm has Acquired 24% Shares in NPK Biotest, a Belarus

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Olainfarm has Acquired 24% Shares in NPK Biotest, a Belarus Based Company

Olaine, 2016-09-08 15:48 CEST (GLOBE NEWSWIRE) -- “We plan to have NPK Biotest not only as our production platform, helping us and our daughter companies to have easier access to Belarus market, but the acquisition will also add Group’s product portfolio with numerous herbal teas and their mixtures,“ says Valerijs Maligins, Chairman of the Board of AS “Olainfarm”.

NPK Biotest is one of the first private pharmaceutical companies in Belarus. Group of scientists of Belarussian Academy of Sciences established it in 1990 in Hrodna.  The company now is producing natural herbal medicines and food supplements.  Its product portfolio includes more than 100 herbal teas, mixtures and powders. NPK Biotest owns four pharmacies in Hrodna. Company’s sales in 2015 were 2.7 million euros..

Olainfarm Group includes Latvian green pharma company Silvanols, chain of pharmacies of Latvijas aptieka, producer of elastic medical products Tonus Elast and producer of eco-cosmetics SIA Kiwi Cosmetics.

Consolidated profit of Olainfarm in 2015 was 15.3 million euros, which is an increase by 25% compared to 2014 and by 8% compared to 2012, when the previous profit record of 14.2 million was set.  Major sales markets of the Group in 2015 were Russia, Latvia, Ukraine, Belarus and The Netherlands.

 JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

         Information prepared by:                    Salvis Lapins          JSC Olainfarm          Member of the Management Board          Rupnicu iela 5, Olaine, Latvia, LV 2114          Phone: +371 6 7013 717          Fax: +371 6 7013 777          E-mail: Salvis.Lapins@olainfarm.lv

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Discovering Innovation: Smitty's Car Wash on Public Television

Updated Category News Views 332

Innovation at Smitty's Car Wash Viewers are in for an enlightening experience as the show "Empowered with Meg Ryan" spotlights Smitty's Car Wash, a pioneer in the express tunnel car wash industry. This segment promises to challenge traditional notions of car washing, showcasing how modern methods and technology integrate to create not just services, but transformative...

Continue Reading
ASPCA® Expands Veterinary Services with New Clinic Opening

Updated Category News Views 144

ASPCA® Opens New Community Veterinary Clinic in New York The ASPCA Community Veterinary Clinic, supported by The Rachael Ray Foundation, is set to meet the needs of many pets in the local area. This opening in New York City is a crucial advancement in providing vital veterinary care to communities in need. Veterinary Services That Are Within Reach Thousands of pets in...

Continue Reading
Big Boost for European Innovation with Novo Nordisk Foundation's Grant

Updated Category News Views 91

Novo Nordisk Foundation Boosts Innovation Funding In a groundbreaking move to enhance innovation in Europe, the Novo Nordisk Foundation is investing up to DKK 5.5 billion (approximately EUR 736 million) into the BioInnovation Institute (BII). This funding is set to play a transformative role in supporting entrepreneurs and startups within the life sciences sector....

Continue Reading
Legal Challenges for 3D Systems: Investor Action Recommended

Updated Category News Views 165

Overview of the Legal Situation Recent events surrounding 3D Systems Corporation have raised significant concerns among investors. The company is currently facing a class action lawsuit that alleges violations of securities laws. Investors in 3D Systems are encouraged to stay informed about the progress of this legal challenge and consider their options moving forward....

Continue Reading
Inhibikase Therapeutics Updates: Q2 2025 Financial Overview

Updated Category News Views 135

Inhibikase Therapeutics Q2 2025 Financial Update Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is making notable strides as a clinical-stage pharmaceutical company dedicated to developing innovative therapeutics aimed at addressing cardiopulmonary diseases, particularly Pulmonary Arterial Hypertension (PAH). Recently, they announced their financial results for the second...

Continue Reading